Our previous studies in AML models have shown that the long-acting pegylated crisantaspase pegcrisantaspase (PegC) synergizes with Ven and the anti-leukemic activity of Ven-PegC is associated with the inhibition of cap-dependent mRNA translation and downregulation of MCL-1 expression (5). The gene discussed is MCL1; the disease is acute myeloid leukemia.